Vnitr Lek 2016, 62(4):263-267

Diuretic treatment in patients with acute pulmonary edema did not produces severe hyponatremia or hypokalemia

Jozef Kaluľay*, Veronika Pokorná, Svetlana Bodíková, Natália Vahančíková, Peter Pon»uch
IV. interná klinika LF UK a UN Bratislava, Nemocnica sv. Cyrila a Metoda, Slovenská republika

Introduction:
One of the risks of diuretic therapy for pulmonary edema is the development of hyponatremia and hypokalemia with pro-arrhythmic potential. The aim of our study was to analyze the incidence of hyponatremia and hypokalemia after the first day of treatment in a real clinical practice.

Methods:
We performed a retrospective analysis of data obtained from medical records. We included all patients with pulmonary edema admitted to the coronary care unit, only patients which died within the first day of treatment were excluded. Absolute dose of administered furosemide, total fluid intake and urine output, saline and pottasium intake were analyzed. Nonparametric paired Wilcoxon test was used to compare natrium and pottasium levels changes.

Results:
37 patients were included into analysis. The median dose of furosemide administered during the first day of treatment was 120 mg (IQR 20-300 mg). Median diuresis was 2 400 ml (IQR 1 425-3 225 ml). The median of difference between diuresis and total fluid intake was 315 ml (IQR 538-1 380 ml). Wilcoxon test confirmed a prevailing statistically significant trend of slight rise in serum sodium within the first day of treatment (serum sodium 138.0 IQR 132.8-139.6 vs 138.1 IQR 134,0-141,7 mmol/l, p = 0.0046). The difference in serum potassium was not statistically significant (serum potassium 4.2 IQR 3.9-4.8 vs 4.2, IQR 3.8-4.8 mmol/l).

Conclusion:
Results did not confirmed the need for a substitution of sodium and potassium losses during the first day of diuretic therapy to prevent hyponatriemia and hypokalemia in patients with pulmonary edema.

Keywords: furosemide; hyponatremia; pulmonary edema

Received: September 8, 2015; Accepted: January 9, 2016; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaluľay J, Pokorná V, Bodíková S, Vahančíková N, Pon»uch P. Diuretic treatment in patients with acute pulmonary edema did not produces severe hyponatremia or hypokalemia. Vnitr Lek. 2016;62(4):263-267.
Download citation

References

  1. Llorens P, Miró Ó, Herrero P et al. Clinical effects and safety of different strategies for administering intravenous diuretics in acutely decompensated heart failure: a randomised clinical trial. Emerg Med J 2014; 31(9): 706-713. Go to original source... Go to PubMed...
  2. Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797-805. Go to original source... Go to PubMed...
  3. Pickkers P, Dormans TP, Russel FG et al. Direct vascular effects of furosemide in humans. Circulation 1997; 96(6): 1847-1852. Go to original source... Go to PubMed...
  4. Wakai A, McCabe A, Kidney R et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013; 8: CD005151. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD005151.pub2>. Go to original source... Go to PubMed...
  5. Holzer-Richling N, Holzer M, Herkner H et al. Randomized placebo controlled trial of furosemide on subjective perception of dyspnoea in patients with pulmonary oedema because of hypertensive crisis. Eur J Clin Invest 2011; 41(6): 627-634. Go to original source... Go to PubMed...
  6. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351(9100): 389-393. Go to original source... Go to PubMed...
  7. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787-1847. Erratum in Eur Heart J 2013; 34(2): 158. Go to original source... Go to PubMed...
  8. Shah RV, McNulty S, O'Connor CM et al. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Am Heart J 2012; 164(6): 862-868. Go to original source... Go to PubMed...
  9. Gallusova J, Halacova M, Cerny D. Optimal way of administration of high dose intravenous furosemide - continuous infusion or bolus? Vnitř Lék 2014; 60(10): 885-892. Go to PubMed...
  10. Verbrugge FH, Tang WH, Mullens W. Renin-Angiotensin-aldosterone system activation during decongestion in acute heart failure: friend or foe? JACC Heart Fail 2015; 3(2): 108-111. Go to original source... Go to PubMed...
  11. De Vecchis R, Esposito C, Ariano C et al. Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature. Herz 2015; 40(3): 423-435. Go to original source... Go to PubMed...
  12. Ali J, Duke K. Colloid osmotic pressure in pulmonary edema clearance with furosemide. Chest 1987; 92(3): 540-546. Go to original source... Go to PubMed...
  13. Kuwahara T, Asanami S, Kubo S. Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells. Nutrition 1998; 14(6): 496-501. Go to original source... Go to PubMed...
  14. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002; 82(3): 569-600. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.